APUS Subsidiary MindWave Inks 2-Year InsurTech Deal With 20% Token Stake

For APUS shareholders, the announcement represents a diversification catalyst: MindWave's two-year master service agreement with BlockAssure shifts a pharmaceutical subsidiary into recurring blockchain infrastructure services, with development fees paid quarterly and a potential token upside equal to 20% of AssureCoin supply. But because the news comes via company press release and token creation is still planned, investors should treat the 20% allocation as contingent consideration rather than booked value. The contract's multi-year structure and anti-dilution protection, however, provide line-of-sight to a long-term U.S. insurance client.

MindWave Innovations Inc. USA, a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), announced on October 5, 2026 that it has signed a two-year master maintenance and service agreement with Delaware-based BlockAssure Inc. to build, deploy and operate AssureChain, a dedicated subnet of MindChain that will run BlockAssure's insurance and reinsurance operations on-chain. Because both sources are syndicated versions of the company's press release, the terms should be read as the issuer's claims rather than independently verified reporting. Under the announced agreement, MindWave will design, develop, security-audit and deploy AssureChain, then host, operate and maintain it once live. BlockAssure intends to place its full insurance workflow on AssureChain—contracts, policies, premium and payment entries, reinsurance treaties and claims processing—from policy inception through claim settlement. MindChain's stated job is narrower: it provides the settlement layer and anchors AssureChain's records to Ethereum.

“

Second, the agreement provides MindWave an allocation equal to 20% of the total supply of AssureCoin, a digital token BlockAssure plans to create within the MindChain network.

The commercial arrangement has two distinct parts. First, MindWave will earn contracted development fees payable in quarterly installments, with later operating and maintenance fees to be agreed. That gives investors some visibility into near-term development revenue but leaves recurring hosting fees unpriced. Second, the agreement provides MindWave an allocation equal to 20% of the total supply of AssureCoin, a digital token BlockAssure plans to create within the MindChain network. The allocation is fully vested upon delivery, and anti-dilution terms maintain MindWave's 20% share if additional AssureCoin is issued during the term or for two years afterward. Since the token does not exist and its utility, economics and regulatory status are unspecified, the allocation is best treated as contingent consideration, not a liquid balance-sheet asset.

Strategically, the deal matters for Apimeds Pharmaceuticals because it extends a wholly owned subsidiary into U.S. enterprise blockchain infrastructure. APUS is a NYSE American-listed small-cap, and this agreement gives it a multi-year build-and-operate contract with a U.S. client, an expansion beyond its core pharmaceutical operations. Insurance and reinsurance are document- and reconciliation-heavy, so moving policies, premiums and claims onto a permissioned subnet with public anchoring could reduce back-office friction. However, BlockAssure's scale, capital, clients, and regulatory licenses are not disclosed, so the practical impact is hard to quantify. Enterprise blockchain adoption in insurance has historically lagged pilot announcements.